TABLE 2.
Effects of BCAA supplementation on metabolic parameters in obese, prediabetic subjects1
| Low-BCAA | BCAA | Baseline P values | Postintervention P values | |||
|---|---|---|---|---|---|---|
| Baseline | Week 4 | Baseline | Week 4 | |||
| Body weight, kg | 97.2 ± 3.1 | 97.3 ± 3.1 | 97.1 ± 3.0 | 97.3 ± 3.1 | 0.98 | 0.64 |
| Body fat, kg | 38.6 ± 2.6 | 39.1 ± 2.9 | 39.0 ± 2.8 | 39.0 ± 2.9 | 0.93 | 0.45 |
| Muscle mass, kg | 56.7 ± 3.0 | 56.7 ± 3.3 | 56.6 ± 3.2 | 56.8 ± 3.3 | 0.99 | 0.95 |
| BMI, kg/m2 | 34.3 ± 1.0 | 34.3 ± 1.0 | 34.2 ± 1.0 | 34.3 ± 1.0 | 0.99 | 0.87 |
| Systolic blood pressure, mmHg | 116.5 ± 3.8 | 118.1 ± 4.2 | 120.1 ± 3.8 | 130.8 ± 3.6 | 0.16 | 0.02 |
| Diastolic blood pressure, mmHg | 76.3 ± 2.3 | 79.1 ± 2.5 | 77.7 ± 2.9 | 81.5 ± 3.1 | 0.49 | 0.28 |
| Fasting blood glucose,2 mg/dL | 97.6 ± 4.73 | 96.9 ± 2.3 | 96.2 ± 2.2 | 96.8 ± 4.4 | 0.64 | 0.08 |
| Fasting insulin,2 µIU/mL | 17.1 ± 2.53 | 32.4 ± 16.6 | 24.0 ± 7.4 | 18.3 ± 4.9 | 0.82 | 0.28 |
| HOMA-IR2 | 4.2 ± 0.73 | 8.2 ± 4.4 | 6.0 ± 2.0 | 4.8 ± 1.7 | 0.69 | 0.33 |
1Data are expressed as mean ± SE (n = 12). Statistical comparisons were performed with the use of ANOVA with a 2-period crossover design to compare within-subject and between-subject supplementation of either low-BCAA or BCAA powder supplements. P values are 2-sided and presented for mean group differences at baseline and postintervention by the BCAA group. BCAA, branched-chain amino acid; OGTT, oral-glucose-tolerance test.
2Baseline and postintervention P values from repeated-measures analysis of variance models with 2-period crossover design based on outcomes derived from the OGTT (at 0, 30, 60, 120 min).
3OGTT means at time 0 for baseline and at time 0 after intervention.